Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
Status:
Withdrawn
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV
ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL
Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion
criteria will be recruited to this trial and treated in this open label, phase 2 trial with
the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from
the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will
continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard
lugano criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Singapore General Hospital
Collaborators:
National Cancer Center Singapore, Singapore National University Hospital, Singapore Raffles Hospital, Singapore